Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer

Plasma cell-free tumor DNA, or circulating tumor DNA (ctDNA), from liquid biopsy is a potential source of tumor genetic material, in the absence of tissue biopsy, for EGFR testing. Our validation study reiterates the clinical utility of ctDNA next generation sequencing (NGS) for EGFR mutation testin...

Descripción completa

Detalles Bibliográficos
Autores principales: Veldore, Vidya H, Choughule, Anuradha, Routhu, Tejaswi, Mandloi, Nitin, Noronha, Vanita, Joshi, Amit, Dutt, Amit, Gupta, Ravi, Vedam, Ramprasad, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757203/
https://www.ncbi.nlm.nih.gov/pubmed/29379323
http://dx.doi.org/10.2147/LCTT.S147841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757203/
https://www.ncbi.nlm.nih.gov/pubmed/29379323
http://dx.doi.org/10.2147/LCTT.S147841

Ejemplares similares